Deinove (ALDEI)

Business description

Deinove is a biotech company that discovers, develops and manufactures compounds of industrial interest stemming from rare bacteria and intended for the health, nutrition and beauty markets.

Stock data

Market cap.€25.2m
Last close€2.14
High / Low (52 weeks)€2.2 / €1.6
Stock market listingEG
Forecast net debt (€m)5.1
Forecast gearing ratio (%)2716
SectorAlternative Energy

Price performance

Relative *20.521.2(4.9)

* % Relative to local index

Other companies in sector Show

Company news

Deinove SA (ALDEI) Dips -1.04% on Jan 25

Thu, 25 Jan 2018 08:03:45 GMT

DEINOVE and ARBIOM join forces to develop a "carbon-free" chemical industry

Mon, 14 Mar 2016 18:00:00 GMT

Deinove SA (ALDEI) Plunges -3.394% on Feb 18

Sun, 18 Feb 2018 10:30:00 GMT

The Digest's 2015 6-Minute Country Guide to France's Advanced Bioeconomy

Wed, 16 Sep 2015 08:01:35 GMT

Cerner Corporation (CERN) Analysts See $0.58 EPS

Sat, 13 Jan 2018 19:18:04 GMT

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (c) P/E (x) P/CF (x)
2015A 0.5 (7.3) (7.3) (66.8) N/A N/A
2016A 0.8 (7.0) (6.9) (64.6) N/A N/A
2017E 0.8 (7.9) (8.6) (65.7) N/A N/A
2018E 2.9 (5.8) (6.8) (44.1) N/A N/A

Last updated on 19/01/2018

Investment summary

At the end of 2017, Deinove announced the launch of the industrial production of its first carotenoid. The initial batches of the carotenoid will be produced in Q118, with the commercial launch of the project scheduled for Q2. Although the structure of the carotenoid has yet to be revealed, we understand that Deinove is targeting the premium end of the market. In November 2017, Deinove had also previously announced that, in partnership with Greentech, it was in the testing phase with six bacterial strains (now reduced to three) to select the final active ingredient for marketing. Greentech plans to market the selected ingredient in 2018. We do not rule out the launch of additional strains in due course. The two announcements provide comfort that Deinove is well placed to meet our FY18 forecasts.

Last updated on 02/02/2018

Industry outlook

Environmentalism will underpin growth in green chemistry, and the growing antimicrobial resistance to current antibiotics will demand the discovery of new antibiotic structures.

Last updated on 02/02/2018

Key management

Dr Philippe Pouletty, Chairman
Emmanuel Petiot, CEO
Julien Coste, CFO

Company address

22 rue Leon Jouhaux
75010 Paris
01 42 03 27 37
View website